Voigt, Isabel
Akgün, Katja
Inojosa, Hernan
Haas, Judith
Temmes, Herbert
Meuth, Sven G.
Giovannoni, Gavin
Ziemssen, Tjalf https://orcid.org/0000-0001-8799-8202
Funding for this research was provided by:
European Regional Development Fund (grant number 100375301)
Technische Universität Dresden
Article History
Received: 20 December 2023
Accepted: 2 July 2024
First Online: 18 November 2024
Declarations
:
: Not applicable.
: Not applicable.
: IV declares that she has no competing interests.KA received personal compensation from Roche, Sanofi, Novartis, Merck, Teva, and BMS for consulting or speaker service.HI received speaker honoraria from Roche and financial support for research activities from Teva, Biogen and Alexion.JH declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.HT has no personal pecuniary interests to discluse, other than being the Secretary General of the German Multiple Sclerosis Society, Federal Association (DMSG), which recently received funding from a range of public and corporate sponsors, including G-BA, The German MS Trust, Biogen, Bristol Myers Squibb, Hexal, Merck, Novartis, Ottobock, Roche, Sanofi and Viatris.SGM declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.GG reports: In the last two years, GG has received compensation for serving as a consultant or speaker for or has received research support from Aurinia Pharmaceuticals, Biogen, BMS-Celgene, GlaxoSmithKline, Janssens/J&J, Japanese Tobacco, Merck KGaA/EMD Serono, Moderna, Novartis, Sandoz, Sanofi and Roche/Genentech.TZ reports the following: a scientific advisory board and/or consulting for Biogen, Roche, Novartis, Celgene, and Merck; compensation for serving on speakers bureaus for Roche, Novartis, Merck, Sanofi, Celgene, and Biogen; and research support from Biogen, Novartis, Merck, and Sanofi.